Follow us on:

INTERVIEW: ECO Animal Health Group plc Another Strong Performance

ECO Animal Health Group plc (LON: EAH) CEO Marc Loomes joins DirectorsTalk to discuss final results for the year ended 31 March 2019. Marc explains what has driven the growth, why expenditure is set to rise, the benefit of transferring it’s Aivlosin API manufacturing process to a new facility in China, the impact of African Swine Fever and the good growth territories.

ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.

Find more news, interviews, share price & company profile here for:Eco Animal Health Group plc

Share this interview

Other Interviews

More News

ECO Animal Health Group CFO Christopher Wilks purchases shares in company April 1, 2022
ECO Animal Health Group pleased with recent trading March 15, 2022
ECO Animal Health expects revenue in line with current market expectations January 12, 2022
ECO Animal Health appoint Tracey James as a Non-Executive Director December 1, 2021
ECO Animal Health Group conducting a live presentation on Tuesday 30th November November 23, 2021
ECO Animal Health Group Chinese market recovery expected to result in improved trading September 16, 2021
ECO Animal Health Group PBT increased significantly to £20.3m July 26, 2021
Eco Animal Health Group revenue and EBITDA significantly ahead of market expectations March 8, 2021
ECO Animal Health Group report solid recovery in key markets February 4, 2021
ECO Animal Health receive marketing authorisation for Aivlosin® Water Soluble Granules in the USA and in Canada January 13, 2021

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.